Reaction

Product Solubility Abnormal reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 4,928 reports · 47 co-occurring drugs

As of the last recalculation, Product Solubility Abnormal appears in 4,928 FAERS reports alongside 47 co-occurring drug terms. The strongest observed disproportionality signal is CHOLESTYRAMINE (PRR 64.8).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Cholestyramine	179	64.8	65.8
Patiromer	107	33.4	33.6
Buprenorphine	383	18.9	18.9
Asenapine Maleate	28	13.7	13.8
Polyethylene Glycol 3350	279	13.0	13.0
Rizatriptan Benzoate	22	9.2	9.2
Nitroglycerin	112	9.0	9.0
Loperamide Hydrochloride And Dimethicone	64	8.5	8.5
Somatropin	106	6.2	6.2
Estradiol Gel 0.1%	65	6.1	6.2
Estradiol Transdermal	65	6.1	6.1
Rimegepant Sulfate	18	6.0	6.0
Buprenorphine Hydrochloride, Naloxone Hydrochloride	31	5.5	5.5
Hyoscyamine Sulfate	10	4.6	4.6
Miconazole Nitrate	9	4.4	4.4
Estradiol	84	4.2	4.2
Loratadine And Pseudoephedrine Sulfate	7	3.7	3.7
Desvenlafaxine Succinate	23	3.6	3.6
Guaifenesin	25	3.5	3.5
Metformin Hydrochloride	47	3.4	3.4
Primidone	8	3.3	3.3
Sucralfate Oral	11	3.3	3.3
Sucralfate Oral Suspension	11	3.3	3.3
Testosterone	18	3.3	3.3
Metformin Hydrochloride Extended-Release Tablets	43	3.2	3.2
Teduglutide	10	3.1	3.1
Glipizide	44	3.1	3.1
Isosorbide Mononitrate	15	3.1	3.1
Metformin Hydrochloride Tablets	41	3.0	3.0
Metformin Hydrochloride Tablet	41	3.0	3.0
Tizanidine	17	3.0	3.0
Icosapent Ethyl	6	3.0	3.0
Instalax Polyethylene Glycol 3350	8	2.7	2.7
Polyethylene Glycol 400	8	2.7	2.7
Azelastine	11	2.6	2.6
Upadacitinib	47	2.4	2.4
Nicotine Polacrilex	22	2.4	2.4
Fentanyl Citrate	10	2.4	2.4
Testosterone Cypionate	5	2.4	2.4
Lisdexamfetamine Dimesylate	18	2.3	2.3
Sevelamer Carbonate	6	2.2	2.2
Naltrexone	15	2.1	2.1
Linaclotide	12	1.9	1.9
Vilazodone Hydrochloride	4	1.8	1.8
Leuprolide Acetate	28	1.5	1.5
Apalutamide	4	1.4	1.4
Levonorgestrel	55	1.2	1.2

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.